Ebola virus dynamics in mice treated with favipiravir

Madelain V, Oestereich L, Graw F, Thi Huyen Tram Nguyen , De Lamballerie X, Mentre F, Guenther S, Guedj J (2015)

Publication Type: Journal article

Publication year: 2015

Journal

Antiviral Research Elsevier Masson

Book Volume: 123

Pages Range: 70-77

DOI: 10.1016/j.antiviral.2015.08.015

Abstract

The polymerase inhibitor favipiravir is a candidate for the treatment of Ebola virus disease. Here, we designed a mathematical model to characterize the viral dynamics in 20 mice experimentally infected with Ebola virus, which were either left untreated or treated with favipiravir at 6 or 8 days post infection. This approach provided estimates of kinetic parameters of Ebola virus reproduction, such as the half-life of productively infected cells, of about 6 h, and the basic reproductive number which indicates that virus produced by a single infected cell productively infects about 9 new cells. Furthermore, the model predicted that favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6 days after initiation of treatment, respectively. The model could be particularly helpful to guide future studies evaluating favipiravir in larger animals.

Authors with CRIS profile

Frederik Graw

Involved external institutions

National Institute for Health and Medical Research / Institut national de la santé et de la recherche médicale (INSERM) FR France (FR) Bernhard-Nocht-Institut für Tropenmedizin (BNITM) / Bernhard Nocht Institute for Tropical Medicine DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Aix-Marseille University / Aix-Marseille Université FR France (FR)

How to cite

APA:

Madelain, V., Oestereich, L., Graw, F., Thi Huyen Tram Nguyen, ., De Lamballerie, X., Mentre, F.,... Guedj, J. (2015). Ebola virus dynamics in mice treated with favipiravir. Antiviral Research, 123, 70-77. https://doi.org/10.1016/j.antiviral.2015.08.015

MLA:

Madelain, Vincent, et al. "Ebola virus dynamics in mice treated with favipiravir." Antiviral Research 123 (2015): 70-77.

BibTeX: Download